Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A method for preparing multifunctional sodium alginate scaffolds embedded with drug-loaded microspheres using 3D printing technology based on in-situ emulsification

A sodium alginate, 3D printing technology, applied in pharmaceutical formulations, microcapsules, drug delivery and other directions, can solve the problems of lack of antibacterial and anti-inflammatory stents, poor mechanical properties of stents, low osteogenic activity, etc., to avoid toxic side effects, mechanical Performance enhancement, the effect of enhancing osteogenic activity

Active Publication Date: 2022-02-15
FUJIAN NORMAL UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, pure sodium alginate scaffolds have poor mechanical properties and low osteogenic activity, so they are limited in practical application, and the constructed scaffolds lack antibacterial and anti-inflammatory activities, which are prone to bacterial infection and concurrent bone grafting. inflammatory response leading to surgical failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for preparing multifunctional sodium alginate scaffolds embedded with drug-loaded microspheres using 3D printing technology based on in-situ emulsification
  • A method for preparing multifunctional sodium alginate scaffolds embedded with drug-loaded microspheres using 3D printing technology based on in-situ emulsification
  • A method for preparing multifunctional sodium alginate scaffolds embedded with drug-loaded microspheres using 3D printing technology based on in-situ emulsification

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] 1) Preparation of amino-modified polylactic acid: Dissolve poly-L-lactic acid particles in 1,4-dioxane solvent in a 60°C water bath to prepare a homogeneous solution with a concentration of 1 wt%. A 1.2 wt% ethylenediamine aqueous solution was added to the phase solution, reacted for 30 min, cooled to room temperature, and then placed in a freeze dryer at -80 °C to freeze-dry to obtain aminated polylactic acid.

[0022] 2) Preparation of printing paste: Weigh a certain amount of lecithin and sodium alginate and dissolve them in 4 wt% ethanol aqueous solution to obtain a lecithin-dissolved sodium alginate solution, and lecithin-dissolved sodium alginate solution The concentration of lecithin was 1 wt%. Dissolving the amino-modified polylactic acid and ibuprofen drug prepared in step 1) in 1,4-dioxane solvent to obtain a modified polylactic acid solution with ibuprofen drug dissolved, wherein the concentration of the modified polylactic acid is is 2 wt%, and the concentr...

Embodiment 2

[0025] 1) Preparation of amino-modified polylactic acid: Dissolve poly-L-lactic acid particles in 1,4-dioxane solvent in a 60°C water bath to prepare a homogeneous solution with a concentration of 1 wt%. A 1.2 wt% ethylenediamine aqueous solution was added to the phase solution, reacted for 30 min, cooled to room temperature, and then placed in a freeze dryer at -80 °C to freeze-dry to obtain aminated polylactic acid.

[0026] 2) Preparation of printing paste: Weigh a certain amount of lecithin and sodium alginate and dissolve them in 4 wt% ethanol aqueous solution to obtain a lecithin-dissolved sodium alginate solution, and lecithin-dissolved sodium alginate solution The concentration of lecithin was 3 wt%. Dissolving the amino-modified polylactic acid and minocycline drug prepared in step 1) in 1,4-dioxane solvent to obtain a modified polylactic acid solution in which minocycline drug is dissolved, wherein the modified polylactic acid The concentration of lactic acid was 3 ...

Embodiment 3

[0029] 1) Preparation of amino-modified polylactic acid: Dissolve poly-L-lactic acid particles in 1,4-dioxane solvent in a 60°C water bath to prepare a homogeneous solution with a concentration of 1 wt%. A 1.2 wt% ethylenediamine aqueous solution was added to the phase solution, reacted for 30 min, cooled to room temperature, and then placed in a freeze dryer at -80 °C to freeze-dry to obtain aminated polylactic acid.

[0030] 2) Preparation of printing paste: Weigh a certain amount of lecithin and sodium alginate and dissolve them in 4 wt% ethanol aqueous solution to obtain a lecithin-dissolved sodium alginate solution, and lecithin-dissolved sodium alginate solution The concentration of lecithin is 2 wt%. Dissolving the amino-modified polylactic acid, loxoprofen sodium and vancomycin drug prepared in step 1) in 1,4-dioxane solvent to obtain loxoprofen sodium and vancomycin drug dissolved Modified polylactic acid solution, wherein the concentration of modified polylactic aci...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for preparing a multifunctional sodium alginate scaffold embedded with drug-loaded microspheres by using a 3D printing technology based on in-situ emulsification, and aims to provide a preparation method for a multifunctional bone defect repair scaffold material. It is characterized in that: using the biologically active substance lecithin as an emulsifier, the aminated modified polylactic acid solution dissolved in antibacterial or anti-inflammatory drugs is dispersed in a sodium alginate solution to form a stable emulsion, and then the low temperature 3D printing technology is used to in situ Sodium alginate scaffolds embedded with drug-loaded microspheres were constructed, and divalent strontium ions (Sr 2+ ) as a cross-linking agent to improve the mechanical properties and osteogenic activity of the scaffold. The feature of the present invention is that the prepared scaffold can be individually designed according to the characteristics of the patient's bone defect, and the prepared scaffold has multiple functions such as good biological activity, osteogenic ability, mechanical properties, antibacterial and anti-inflammatory, and has potential in the field of bone tissue engineering. application prospects.

Description

technical field [0001] The invention belongs to the technical field of bone repair biomaterials, and in particular relates to a method for preparing a multifunctional sodium alginate scaffold embedded with drug-loaded microspheres by using a 3D printing technology based on in-situ emulsification. Background technique [0002] The repair and treatment of large-sized bone defects caused by partial bone loss in patients caused by various traumas, tumor resections, or infections is a huge challenge in clinical medicine at present. Due to the limitations of autologous bone grafting, allogeneic bone grafting and artificial bone grafting in the repair of such bone defects, their clinical application is limited due to the limited donor area, easy immune rejection, and lack of osteoinductive activity. Novel regenerative bone defect repair materials with bioactivity and osteogenic ability have become an urgent problem in the field of bone repair. With the continuous development of ti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61L27/18A61L27/20A61L27/54A61L27/56A61L27/58B33Y70/00B33Y80/00
CPCA61L27/18A61L27/20A61L27/54A61L27/58A61L27/56B33Y70/00B33Y80/00A61L2300/406A61L2300/602A61L2300/622A61L2430/02C08L67/04C08L5/04
Inventor 陈顺玉赵利华谢春玲梁青爽肖秀峰
Owner FUJIAN NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products